In both pancreatic and periampullary adenocarcinoma and esophageal and gastric adenocarcinoma, PODXL was proven to be an independent predictor of poor outcome.31, 32 In the case of CRC, Larsson et al33 detected PODXL using antibody HPA2110 and analyzed its expression levels in 536 CRC cases, demonstrating that the PODXL was an independent factor of poor prognosis and may be a useful marker to stratify patients for adjuvant chemotherapy. This evidence concerns the gene PODXL and colorectal carcinoma.